Ito Yasuhiro, Fukushima Mitsuhiro, Tomoda Chisato, Inoue Hiroyuki, Kihara Minoru, Higashiyama Takuya, Uruno Takashi, Takamura Yuuki, Miya Akihiro, Kobayashi Kaoru, Matsuzuka Fumio, Miyauchi Akira
Department of Surgery, Kuma Hospital, Chuo-ku, Kobe, Hyogo, Japan.
Endocr J. 2009;56(6):759-66. doi: 10.1507/endocrj.k09e-025. Epub 2009 Jun 9.
Lymph node metastasis is an important clinicopathological feature of papillary thyroid carcinoma (PTC). PTC having clinically apparent lateral node metastasis detectable on preoperative imaging studies (N1b) is known to show a dire prognosis. However, N1b cases include various levels of biological aggressiveness, depending on the size, number, laterality and invasiveness of metastatic nodes. We investigated differences in the prognoses of 621 N1b patients based on these features and compared their prognoses with those of 4297 patients without clinically apparent metastasis (N0) and 125 patients with clinically apparent central node metastasis only (N1a). Disease-free survival (DFS) and cause-specific survival (CSS) of N1b or N1a patients were significantly worse than those of N0 patients, but the prognosis of N1b patients did not differ from that of N1a patients. In the subset of N1b patients, metastatic nodes larger than 3cm, extranodal extension, or 5 or more clinically apparent metastatic nodes independently affected DFS and a combination of the former two features also showed an effect on CSS on multivariate analysis. Prognosis of N1b patients who had none of these features did not differ from that of N1a patients. It is therefore suggested that N1b patients having metastasis larger than 3cm, those showing extranodal extension, and those having 5 or more clinically apparent metastasis should regarded as high-risk, and that careful surgical treatment and postoperative follow-up are necessary.
淋巴结转移是甲状腺乳头状癌(PTC)重要的临床病理特征。术前影像学检查可发现有临床明显侧方淋巴结转移(N1b)的PTC预后较差。然而,N1b病例根据转移淋巴结的大小、数量、部位及侵袭性存在不同程度的生物学侵袭性。我们基于这些特征研究了621例N1b患者预后的差异,并将其预后与4297例无临床明显转移(N0)的患者及125例仅伴有临床明显中央区淋巴结转移(N1a)的患者进行比较。N1b或N1a患者的无病生存期(DFS)和病因特异性生存期(CSS)显著差于N0患者,但N1b患者的预后与N1a患者并无差异。在N1b患者亚组中,转移淋巴结大于3cm、淋巴结外侵犯或5个及以上临床明显转移淋巴结独立影响DFS,前两项特征的组合在多因素分析中也对CSS有影响。无上述任何特征的N1b患者的预后与N1a患者无异。因此,建议将转移淋巴结大于3cm、有淋巴结外侵犯及有5个及以上临床明显转移的N1b患者视为高危患者,需要进行仔细的手术治疗及术后随访。